Diffuse Sclerosing Osteomyelitis of the jaw DSO
Conditions
Interventions
A 30-mg dose of pamidronate will be administrated intravenously for 4 hours under hospitalization. One treatment is a single dose
Sponsors
Kimura Taku
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients suspected diffuse sclerosing osteomyelitis of jaw clinically in Hokkaido university hospital. The final diagnosis of DSO is determined as follows in the conference by oral surgery specialist. 1Recurrent pain and swelling of the mandible, with no sign of infection with microorganisms. 2CT images of DSO patients showed an intermingled sclerotic and lytic pattern in the cortex and medulla. 3Antimicrobial treatment has not proved to be effective. 4No history of irradiation to the maxillofacial area and received long-term bisphosphonate therapy. Inclusion Criteria 1over 15 years old 2written informed consent 3Performance Status 0 or 1
Exclusion criteria
Exclusion criteria: 1)Patients diagnosed Anti-resorptive agents-related ONJ 2)Patients who received other bisphosphonate. 3)Children of 15 years or under. 4)pregnancy, nursing woman or possibly pregnant woman. 5)Patients with severe renal disorders(BUN:=<1.5 upper limit of normal,Cr:=<1.5 upper limit of normal) 6)patients who are contraindications for Voltaren 7)patient that physician determined inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of Visual Analogue Scale (VAS) of pain after administaration of bisphosphonate | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Safety: general morbidities,side effects 2) SUVmax of the FDF-PET 3) correlation between Bone scintigraphy and pain area | — |
Contacts
Public ContactTakuya Asaka
HokkaidoUniversityHospital
Outcome results
None listed